Maribel Gonzalez
Payments from drug & device makers
Across 220 payments — averaging $23.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$2K
- Johnson & Johnson$476
- Theratechnologies Inc.$252
- Merck$191
- Napo Pharmaceuticals Inc$147
- plus $362 from 6 others
What the payments were for
- Food & beverage$5,10997%
- Education$1353%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 85 | $2,051 |
| Gilead | 69 | $1,764 |
| Johnson & Johnson | 24 | $476 |
| Theratechnologies Inc. | 12 | $252 |
| Merck | 9 | $191 |
| Napo Pharmaceuticals Inc | 7 | $147 |
| Janssen Products, LP | 2 | $135 |
| AbbVie | 5 | $104 |
| Janssen Scientific Affairs, LLC | 4 | $64 |
| Tolmar, Inc. | 1 | $28 |
| GSK | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,244 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 84 | $324,089 |
| DovatoDolutegravir Sodium/Lamivudine | 55 | $159,807 |
| DescovyEmtricitabine/Tenofov Alafenam | 43 | $87,286 |
| TivicayDolutegravir Sodium | 39 | $86,505 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 21 | $79,753 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 16 | $58,203 |
| JulucaDolutegravir/Rilpivirine | 13 | $42,981 |
| PrezcobixDarunavir/Cobicistat | 16 | $37,453 |
| Darunavir | 22 | $25,641 |
| Ritonavir | 14 | $2,605 |
| Omeprazole | 30 | $317 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $298 |
| Rosuvastatin Calcium | 35 | $203 |
| Atorvastatin Calcium | 48 | $184 |
| Pantoprazole Sodium | 12 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $1,764 | $491,128148 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Triumeq, Juluca | $2,051 | $347,496123 claims |
| Johnson & JohnsonPrezcobix | $476 | $37,45316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Miami
- Stephanie MompointMiami$4.5M
- Itsel Cardenas RamonMiami$1M
- Patrick SzarazMiami$327K
- Yamila MelendezMiami$212K
- Suzan RosenMiami$129K
- Felipe NovoaMiami$110K
- Pamela DudkiewiczMiami$89K
- Stacy FeemsterMiami$51K
- John HuffakerVenice$8M
- Miguel TrujilloMiami Gardens$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.